NCT05620628 2026-01-21Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)Samsung Medical CenterPhase 2 Recruiting25 enrolled
NCT03228667 2026-01-14QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsImmunityBio, Inc.Phase 2 Active not recruiting40 enrolled
NCT04817826 2025-06-10INFINITYGruppo Oncologico del Nord-OvestPhase 2 Active not recruiting31 enrolled
NCT03959293 2024-07-08Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction AdenocarcinomaFederation Francophone de Cancerologie DigestivePhase 2 Active not recruiting107 enrolled
NCT04893252 2022-11-30Vactosertib and Durvalumab in Gastric CancerNational Cancer Center, KoreaPhase 2 Unknown55 enrolled
NCT03544723 2020-06-09Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.MultiVir, Inc.Phase 2 Unknown40 enrolled